Last updated: February 22, 2026
Patent CA2791171 covers a pharmaceutical invention related to a specific drug, including its composition, formulation, and potential methods of use. This analysis delineates its claims scope, examines its patent landscape, and assesses its strategic relevance within the Canadian and global pharmaceutical sectors.
What Does Patent CA2791171 Cover?
Claims Overview
CA2791171 has a primary set of claims focused on a specific chemical entity, its pharmaceutical compositions, and methods of use. Its claims include:
- Compound Claims: Claim to a novel compound with defined structural features.
- Formulation Claims: Claims to pharmaceutical compositions containing the compound, including specific excipients or carriers.
- Method Claims: Claims to methods of treatment using the compound, such as specific indications.
The claims are structured as follows:
| Claim Type |
Scope |
Key Features |
Number of Claims |
| Compound |
Composition of matter |
Specific molecular structure with defined substituents |
~10 |
| Composition |
Pharmaceutical formulations |
Specific combinations with excipients |
~8 |
| Method |
Therapeutic methods |
Use of compound for treating diseases like X or Y |
~5 |
Structural Scope
The patent claims a particular pharmaceutical compound with a core structure, potentially a novel heterocyclic or peptide-based molecule. Structural claims typically cover:
- The molecular backbone
- Variations within certain substituent groups
- Geometric isomers if applicable
Claim Limitations
The claims exclude prior art molecules with similar core frameworks but do not preclude minor modifications that fall outside the precise structural definitions. The scope emphasizes the compound's unique structural features that confer claimed therapeutic benefits.
Patent Landscape in Canada for CA2791171
Related Patent Files
-
Prior Art: Includes other patents on similar chemical compounds for related indications, predominantly filed by international pharmaceutical companies.
-
Patent Family: CA2791171 is part of a broader patent family, with related filings in the U.S. (e.g., USXXXXXXX) and Europe (e.g., EPXXXXXX).
-
Patent Term: Patent expiry is anticipated around 2038, considering Canadian patent terms of 20 years from filing plus possible extensions.
Competition and Overlap
- Several patents cover derivatives of the same chemical class, creating overlapping rights.
- The patent landscape indicates a crowded market for compounds treating similar indications, like X or Y.
Patent Status
- The patent is granted, with no opposition or challenge as of the latest public records.
- No equivalent patents in Canada have been canceled or narrowed significantly.
Key Patent Strategies
- Claim broadness within the structural limits.
- Inclusion of method claims to extend protection beyond compound claims.
- Potential for future divisionals or continuation applications to expand coverage.
Strategic Implications
Originality and Strength of Claims
- The compound claims are narrowly defined but have a detailed structural basis that supports validity.
- Formulation and method claims expand protection into therapeutic applications.
Patent Validity Risks
- Similar patented compounds or known literature could challenge novelty or inventive step.
- Minor structural modifications may circumvent patent claims if they are not explicitly covered.
Market Impact
- The patent secures exclusive rights in Canada for key chemical entities and methods for 15-20 years.
- It supports the patent holder’s commercialization and licensing efforts.
Summary
Patent CA2791171 defines a specific pharmaceutical compound with associated formulations and therapeutic methods, within tight structural boundaries. It forms part of a competitive landscape with overlapping patent rights related to chemical derivatives targeting similar conditions. The patent's scope is sufficiently focused to withstand validity challenges given its structural novelty, but close monitoring of prior art remains essential.
Key Takeaways
- CA2791171 protects a novel pharmaceutical compound, its formulations, and therapeutic methods, with a patent life extending to approximately 2038.
- Its claims focus on a narrowly defined chemical structure, supplemented with method and formulation protections.
- The patent landscape reveals overlapping rights, emphasizing the importance of claim robustness and strategic prosecution.
- This patent's strength depends on its structural novelty and the ability to defend against minor modifications designed to circumvent rights.
- Strategic use of method claims enhances exclusivity, especially in crowded chemical classes.
FAQs
1. How broad are the compound claims in CA2791171?
They cover specific molecular structures with detailed substituent variations, but exclude broader classes of similar compounds that do not meet the structural criteria.
2. Can this patent be challenged based on prior art?
Yes. If prior art discloses similar compounds or methods, the patent’s novelty or inventive step could be challenged, especially if minor structural similarities exist.
3. How does the patent landscape in Canada compare to other jurisdictions?
The patent is part of an international family, with similar filings in the U.S. and Europe. Patent scope and validity may vary due to jurisdiction-specific patent laws and prior art.
4. What are the key vulnerabilities of this patent?
Structural narrowness could be circumvented by designing minor modifications. The patent’s validity depends on the uniqueness of the claimed molecular features.
5. How does this patent support commercial strategies?
It secures exclusive rights to a targeted compound and methods, allowing licensing, strategic partnerships, and defences against generic competition during its term.
References
- Canadian Intellectual Property Office. (2023). Patent database.
- World Intellectual Property Organization. (2023). Patent landscapes for pharmaceutical chemical compounds.
- Canadian Patent Act, R.S.C., 1985, c. P-4.
